by Peter Ciszewski | Aug 15, 2018
Vanessa Vogel-Farley, Executive Director, Dup15q Alliance discusses her Alliance and some of the research for Dup15q syndrome, the common name for chromosome 15q11.2-q13.1 duplication syndrome. Dup15q syndrome is the common name for chromosome 15q11.2-q13.1...
by Peter Ciszewski | Aug 14, 2018
Ron Cooper, President and CEO of Albireo, discusses drug development at Albireo, which has a clinical trial in progressive familial intrahepatic cholestasis (PFIC), a rare genetic condition that affects the liver. PFIC is estimated to affect between one in...
by Peter Ciszewski | Aug 13, 2018
Strongbridge Biopharma’s pivotal phase 3 SONICS study evaluating levoketoconazole (Recorlev) for the treatment of endogenous Cushing’s syndrome achieved statistical significance of its pre-specified primary endpoint. According to the company, 30% of patients...
by Peter Ciszewski | Aug 13, 2018
Editor’s Note: This interview was conducted at #BIO2018. Please pardon the background noise. Barry Greene, President of Alnylam, joined the company in 2003 and has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology...
by Peter Ciszewski | Aug 12, 2018
Gail Cawkwell, MD, PhD, Senior Vice President, Medical Affairs at Intercept, provides an overview of the company. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral...
